Latest Intelligence on Pharmaceuticals and Healthcare in Switzerland

Published within

« | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | ... | » »|

Type Product title / description Pub Price
CommentWire
CommentWire

Eczema therapies: Fujisawa gets help as Novartis gains ground

The success of Novartis' [NVS] eczema cream in its first year of sales has caused Fujisawa [FJSPF.PK] to strengthen marketing arrangements for its own eczema drug in the key US market. Fujisawa's initial attempt to go it alone in the US has resulted in slow sales, but the struggle between Novartis and its Japanese rival is only just beginning.

Published By Datamonitor
14 Jul 2003
CommentWire
CommentWire

Ferring: strong R&D base for next generation incontinence treatment

Ferring's next generation of antidiuretics to treat urinary incontinence could make use of pioneering research by Nobel Laureate Professor Agre. The company's close relationship with academia and its own long history of research in the urinary incontinence field should strengthen its position as a leading urology player.

Published By Datamonitor
01 Mar 2004
CommentWire
CommentWire

Genentech/Roche: another indication for the blockbuster Avastin?

Clinical trial data has shown a significant increases in progression-free survival when Avastin is added to standard interferon treatment for first-line metastatic renal cell carcinoma. Although Avastin has already reached blockbuster status, it will need to demonstrate significant clinical benefit in its final results in order to compete with its cheaper, small molecule competitors.

Published By Datamonitor
12 Dec 2006
CommentWire
CommentWire

Genentech/Roche: Avastin suffers a minor setback

Roche has announced that a Phase III trial for Avastin in early-stage colorectal cancer has failed to meet its primary endpoint. Although this setback is unlikely to affect Avastin's sales in its approved indications, it creates a commercially attractive opportunity for rival drug Erbitux to gain first-to-market status in early-stage colorectal cancer.

Published By Datamonitor
22 Apr 2009
CommentWire
CommentWire

Genentech/Roche: significant potential for Avastin in glioma

Clinical phase II trial data has shown a combination of Genentech/Roche's Avastin and Pfizer's Camptosar to confer antitumor activity in the treatment of glioma. Although Avastin has already reached blockbuster status in other indications, the severe unmet needs and lack of alternative treatment options in this patient population mean that, if approved, eventual uptake is likely to be promising.

Published By Datamonitor
19 Feb 2007
CommentWire
CommentWire

Genentech: Avastin may drive it into pole position

Positive trial data for Avastin drove Genentech's [DNA] share price up by almost 25% and parent company Roche's [ROCZ.S] share price by over 5%. Roche and Genentech have partnered to form the largest global player for cancer drugs, and Avastin looks set to provide them with another superstar product. Genentech's future as a major biotech player in the cancer market thus seems assured.

Published By Datamonitor
16 Mar 2005
CommentWire
CommentWire

Genentech: Avastin on track for 2004 launch

Genentech looks set to add Avastin to its growing number of successfully marketed innovative products, judging by the announcement of positive phase III clinical trial results in colorectal cancer patients. The results pave the way for Avastin to be launched in late 2004, making it the first angiogenesis inhibitor available for the treatment of colorectal cancer.

Published By Datamonitor
20 May 2003
CommentWire
CommentWire

Genentech: rejects Roche bid

Genentech has declined the $43.7 billion takeover bid made by Swiss pharmaceutical giant Roche, on the grounds that the offer undervalues the benefits that full-ownership of the US biotech would provide. Genentech's unsurprising decision leaves the door open to further negotiations, with a deal expected to be finalized within the next few months.

Published By Datamonitor
14 Aug 2008
CommentWire
CommentWire

Hepatitis A vaccine: more protection than expected

A new study suggests the hepatitis A vaccine may provide immunity for over 20 years. A new Swiss study predicts that two doses of the hepatitis A vaccine will provide immunity for over 20 years. This is longer than previously thought.<BR />

Published By Datamonitor
13 Dec 2002
CommentWire
CommentWire

Imclone/Merck KGaA: first approval for Erbitux

The Swiss agency for therapeutic products has approved Erbitux for the treatment of patients with colorectal cancer who no longer respond to standard chemotherapy treatment with irinotecan. This is likely to be followed by approval across Europe, where it should provide Merck KGaA [MRK.F] with annual sales of more than $260 million by 2008.

Published By Datamonitor
04 Dec 2003

« | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | ... | » »|

No help is available.